ArticleInternational medical case reports journal2025
Metastatic Adamantinoma of Fibula to the Lungs: A Rare Case Report.
Article in International medical case reports journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adamantinoma is a low-grade, primary malignant bone tumor commonly found in the tibia with or without fibular involvement. Case Presentation: A 21-year-old female patient was admitted to the hospital with a mass on the upper lateral aspect of the left leg. She reported the onset of a small swelling in the left leg eight months prior to admission. It has gradually increased in size to involve the upper leg and part of the knee. The patient had limited range of motion in the knee joint and difficulty leaning on the affected limb. Radiographs showed a cortical-destroying osteolytic lesion at the head of the fibula extending into the surrounding soft tissue. Ultrasound imaging showed a mixed echo formation with indistinct borders and multiple chambers separated by trabeculae demonstrating blood flow. MRI revealed the absence of the fibular head as evidenced by cortical destruction and extension into adjacent soft tissue. CT scan showed a 12×13 cm mass in the left popliteal region extending to the knee margin. Enlarged lymph nodes were noted in the left groin. Multiple small metastases were observed in the lungs. Histologically, atypical epithelial cells and stromal spindle cells were observed. CK and CK19 staining was positive. The patient was treated with Sunitinib 50 mg orally, once daily for 4 weeks, followed by 2 weeks off for 2 cycles. During treatment (after 2 cycles) the tumor showed progressive growth, resulting in decreased function of the affected limb. She was referred to the surgical department where the appropriate surgical amputation was performed. After surgery, the patient's general condition improved. A further CT scan revealed a slight progression of metastatic lesions in the lungs, which prompted the decision to administer chemotherapy, but she refused to continue the treatment and did not receive chemotherapy. Two months later, she presented to the hospital in poor general condition. CT scan revealed extensive and progressive lesions in both lungs, leading to chest pain, hemoptysis, and hypoxia. Despite supportive care, the patient eventually died. Conclusion: This case report presents a rare case of metastatic adamantinoma that did not respond to treatment with Sunitinib.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.